此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management (NoDoubt)

2026年8月18日 更新者:University Hospital, Basel, Switzerland

Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management: a Double-blind, Randomized, Three Arm, Placebo Controlled Trial Assessing the Key Non-opioids Dipyrone (Metamizole) and Ibuprofen

The investigators investigate the efficacy of non-opioid analgesics compared to placebo together with opioid therapy for cancer pain management.

研究概览

详细说明

Pain in cancer is common and can be very debilitating. Approximately half of all people with a tumor experience moderate to severe pain during the course of patient's cancer. Nevertheless, pain management is often difficult because there are not yet enough reliable studies for some medications, especially when used in addition to opioids.

Therefore, the NoDoubt study is investigating whether metamizole and/or ibuprofen - compared to a placebo - in addition to opioids provide better pain relief for cancer patients. The main goal is to reduce pain intensity. The study also examines whether the need for opioids can be reduced. The results could help to establish a clear and standardized practice for the treatment of cancer pain in the future, thus leading to improved care for cancer patients.

研究类型

介入性

注册 (估计的)

318

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Inpatient setting (discharge possible, if patient returns for End of Study Visit)
  • Diagnosis of metastatic or locally advanced cancer
  • Cancer pain as defined by IASP (International Association for the Study of Pain)
  • Cancer pain therapy with opioids indicated for pain management or start thereof at baseline (drug, dose, and route at treating physician's discretion)
  • Average daily pain intensity ≥ 3 on NRS (Numeric Rating Scale)
  • Ability to swallow oral medication
  • Informed Consent as documented by signature

Exclusion Criteria:

  • History of allergy or allergy-like symptoms (bronchospasm, urticaria or severe cutaneous adverse reactions (SCARs)) or hypersensitivity to dipyrone (or other pyrazolones or pyrazolidines) or ibuprofen (or other Non-steroidal anti-inflammatory drug incl. acetylsalicylic acid)
  • Moderate to severe renal insufficiency (creatinine-eGFR (estimated Glomerular Filtration Rate) <45 ml/min)
  • Severe heart failure (New York Heart Association class III-IV)
  • Severe hepatic impairment (liver cirrhosis with ascites) or hepatic porphyria
  • History of agranulocytosis induced by dipyrone (or other pyrazolones or pyrazolidines)
  • Active gastric and/or duodenal ulcers or bleeding
  • History of recurrent gastric and/or duodenal ulcers or gastrointestinal bleeding (≥2 distinct episodes of proven ulceration or bleeding) or increased tendency to bleeding
  • Third trimester of pregnancy
  • Breastfeeding
  • G6PD deficiency
  • Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
  • Intrathecal or epidural opioids or local or regional anesthetic therapy
  • Additional second opioid for co-analgesic effects or other reasons (e.g., methadone, buprenorphine)
  • Initiation of therapy with transdermal therapeutic system (TTS) opioid <48 hours before start of IMP
  • Use of non-opioids with long half-life (i.e., acemetacin, celecoxib, etodolac, etoricoxib, ketorolac, naproxen, piroxicam, tenoxicam)
  • Pain unrelated to cancer (e.g. chronic non-cancer pain [CNCP], postoperative, particularly following coronary artery or cardiopulmonary bypass surgery)
  • Inability to follow study procedures or adhere to protocol (e.g., due to language problems, psychological disorders, dementia)
  • Inability to abstain from other non-opioids (apart from IMP (Investigational Medicinal Product)) during study participation
  • Participation in any interventional study targeted at pain management
  • Participant is a family member or employee of the investigator

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Opioid + Metamizole
Metamizole 4 g/d as: 2 capsules of 500 mg Metamizole each (1000 mg) taken 4 x daily orally.
实验性的:Opioid + Ibuprofen
Ibuprofen 1.2 g/d as: 2 capsules of 150 mg Ibuprofen each (300 mg) taken 4 x daily orally
安慰剂比较:Opioid + Placebo
Placebo 0 g/d as: 2 capsules containing inactive substance (mannitol) taken 4 x daily orally.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in cancer pain
大体时间:up to 5 days

The primary outcome will help to determine whether adding metamizole (dipyrone) or ibuprofen to opioids is more effective than adding placebo in reducing average daily pain intensity (primary outcome) in cancer patients.

- Average of 5-day average daily patient reported pain assessed on days 3 to 7 by numeric rating scale (NRS); The NRS ranges from 0 ("no pain") to 10 ("pain as bad as the patient can imagine")

up to 5 days

次要结果测量

结果测量
措施说明
大体时间
Assessment of equivalence of metamizole and ibuprofen in analgesic potency regarding the pain intensity
大体时间:up to 5 days
Our main secondary outcome will help to investigate whether metamizole and ibuprofen demonstrate similar analgesic potency (are equivalent) regarding the pain intensity. For assessment of equivalence, Average of 5-day average daily patient reported pain assessed on days 3 to 7 by numeric rating scale will be used.
up to 5 days
Time to pain control [in days]
大体时间:up to 7 days
  1. Time until minimal clinically important difference (MCID) of 1 is achieved
  2. Time until PSG is achieved

MCID and PSG achieved (Yes/No) will be assessed daily from day 3 to 7.

up to 7 days
≥30% reduction in daily average pain (Yes/No)
大体时间:up to 7 days
This outcome will be assessed based on the average of daily patient reported pain intensity by NRS at baseline (BL-pain) compared to the daily average pain on the last day of the intervention period (day 7).
up to 7 days
Burden through interference of pain with general activity by NRS
大体时间:up to 8 days
Will be assessed at baseline and daily from day 3 to 7 using item 9 A ("General activity") of the BPI-SF. The NRS ranges from 0 ("does not interfere") to 10 ("completely interferes"). Both outcomes will also be assessed at EOS.
up to 8 days
Burden through interference of pain with mood by NRS
大体时间:up to 8 days
Will be assessed at baseline and daily from day 3 to 7 using item 9 B ("Mood") of the BPI-SF. The NRS ranges from 0 ("does not interfere") to 10 ("completely interferes"). Both outcomes will also be assessed at EOS.
up to 8 days
Number of opioid rescue medications per day
大体时间:up to 8 days
The daily number of IROs (Immediate Release Opioids) will be assessed.
up to 8 days
Number of pain episodes
大体时间:up to 8 days
This outcome will be assessed at baseline, daily between day 3 and 7. It will also be assessed at EOS.
up to 8 days
Duration [in minutes] of pain episodes
大体时间:up to 8 days
This outcome will be assessed at baseline, daily between day 3 and 7. It will also be assessed at EOS.
up to 8 days
Worst pain in the past 24 hours by NRS
大体时间:up to 8 days
This outcome will be assessed at baseline and daily from day 3 to 7 using item 3 of the BPI-SF (Brief Pain Inventory - Short Form). The NRS ranges from 0 ("no pain") to 10 ("pain as bad as the patient can imagine"). It will also be assessed at End of Study Visit (EOS).
up to 8 days
Least pain in the past 24 hours by NRS
大体时间:up to 8 days
This outcome will be assessed at baseline and daily from day 3 to 7 using item 4 of the BPI-SF. The NRS ranges from 0 ("no pain") to 10 ("pain as bad as the patient can imagine"). It will also be assessed at EOS.
up to 8 days
Daily differences in pain intensity measured by NRS
大体时间:up to 7 days
This outcome will be assessed daily from day 3 to day 7 to investigate efficacy over the course of time. The NRS ranges from 0 ("no pain") to 10 ("pain as bad as the patient can imagine")
up to 7 days
Patient's Individual Primary Goal (IPG) achieved
大体时间:8 days

The IPG will be specified at baseline and whether it has been achieved or not will be assessed at EOS based on the specified IPG at baseline.

The IPG reflects variation between individuals' analgesic goals and further individualize symptom assessment by allowing each patient to specify a primary goal regarding the amelioration of the main issue as asked at baseline (i.e., patient's most important item from this list: average pain, pain interference with mood or activity, number or duration of pain episodes, worst pain, other).

8 days
Personal Symptom Goal (PSG) achieved
大体时间:up to 7 days

The PSG will be specified at baseline (NRS 0-10) and whether it has been achieved or not will be assessed daily from day 3 to 7.

Patients are asked at baseline "At what level would you feel comfortable with this symptom?" to identify the maximal symptom intensity they would consider comfortable on the NRS ranging from 0 ("no pain") to 10 ("pain as bad as the patient can imagine").

up to 7 days
Patient Global Impression of Pain Change (PGIC) by verbal rating scale (VRS)
大体时间:day 8
A 7-option rating-of-change scale to assess participant-reported response to pain therapy using a VRS ("very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse").
day 8
Morphine Equivalent Daily Dose (MEDD) (in mg) calculated by compound, dose and application route of IROs (Immediate Release Opioid) and EROs (Extended-release Opioids)
大体时间:up to 7 days

Baseline MEDD and MEDD at EOS will be assessed. This outcome will be assessed daily between day 1 and 7.

MEDD is calculated by multiplying the daily dose of the prescribed opioid (if not already morphine) by a compound-specific, route of application-dependent conversion factor.

The opioid conversion ratios used to calculate MEDD are based on the literature and practical clinical considerations on equianalgesic dosing.

up to 7 days

其他结果措施

结果测量
措施说明
大体时间
Number of patients with ≥30% reduction in pain
大体时间:up to 7 days
For this outcome, the number of patients achieving ≥30% reduction in pain will be assessed, comparing pain at baseline (BL-pain) to the daily average pain on the last day of the intervention (day 7)
up to 7 days
Adherence to protocol and IMP intake
大体时间:up to 7 days

Discharge during d1-d7 will be assessed (Yes/No), including time to discharge after inclusion, if applicable.

IMP intake (i.e., missed doses day d1-d7) will be assessed daily.

up to 7 days
Number of participants that opened the capsules
大体时间:up to 8 days
Administration assessed daily as "Capsules opened: Yes/No".
up to 8 days
Number of participants that received the IMP through an enteral tube
大体时间:up to 8 days
Assessed daily as "Administration through enteral tube": Yes/No, if "capsules opened: Yes"
up to 8 days
Continuation of non-opioid treatment
大体时间:up to 8 days
This will be assessed at EOS based on the clinical decision at physician's discretion (after unblinding). It will be assessed whether the non-opioid is continued, discontinued, switched, or if a (new) non-opioid is initiated. If applicable, the drug and the daily dose (mg/24 h) will be assessed.
up to 8 days
Differences in treatment response based on CRP (C-reactive protein) status at baseline
大体时间:Baseline and day 8
The CRP measured at baseline will be used to exploratively assess whether treatment response differs according to baseline inflammatory status as measured by CRP (i.e., whether baseline inflammation may act as a potential effect modifier of the observed treatment response).
Baseline and day 8
Changes in symptoms at EOS compared to baseline
大体时间:up to 8 days

Using ESAS (Edmonton Symptom Assessment System):

This scale is designed to help assess pain, tiredness, drowsiness, nausea, depression, anxiety, appetite, wellbeing, and shortness of breath. The blank scale can be used to assess "other problems" as needed. Each symptom's severity at the time of assessment is rated from 0 to 10; 0 meaning the symptom is absent and 10 being the worst possible severity.

up to 8 days
Changes in activity levels at EOS compared to baseline
大体时间:up to 8 days
Average activity levels of the past 7 days will be assessed at baseline and at EOS using a NRS (numeric rating scale) ranging from 0 (no activity at all) to 10 (maximum possible activity/the same as in health).
up to 8 days
Accuracy of participant treatment guess
大体时间:up to 8 days
(Correct vs incorrect vs unsure) based on comparison with actual treatment allocation
up to 8 days
Incidence of (serious) adverse events ((S)AEs)
大体时间:up to 8 days
up to 8 days
Type and duration of (S)AEs
大体时间:up to 8 days
up to 8 days
Number of dropouts due to decrease in creatinine-estimated (e)GFR <30 ml/min and/or ≥1.5-fold increase in baseline serum creatinine attributed to ibuprofen
大体时间:up to 8 days
up to 8 days
Number of dropouts due to clinically relevant decrease in leukocyte count (≥50% from baseline) attributed to metamizole
大体时间:up to 8 days
up to 8 days
Changes in performance status (ECOG) at EOS compared to baseline
大体时间:up to 8 days
Using the ECOG (Eastern Cooperative Oncology Group) performance status. It describes a patient's level of functioning based on the ability to perform self-care, daily activities, and physical activities (e.g., walking and working). The scale runs from 0 to 5, where lower numbers indicate better functioning. However, as 5 indicates death, only 0 to 4 are used for assessment of this outcome.
up to 8 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Christopher Boehlke, Prof. Dr.、University Hospital, Basel, Switzerland

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2029年11月1日

研究完成 (估计的)

2029年11月1日

研究注册日期

首次提交

2026年6月26日

首先提交符合 QC 标准的

2026年6月26日

首次发布 (实际的)

2026年7月6日

研究记录更新

最后更新发布 (实际的)

2026年8月19日

上次提交的符合 QC 标准的更新

2026年8月18日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅